Agilent Technologies Inc. (NYSE: A) and SomaLogic Inc. (a privately held biotechnology company) announced today that they have entered into an agreement to expand access to SomaLogic’s unbiased protein biomarker discovery platform.
The companies will initially place SomaLogic’s SOMAscan proteomic assay, which employs custom Agilent microarrays in its workflow, in select academic and contract research centers. Although the SOMAscan assay is already available to researchers directly from SomaLogic as a service, this planned roll-out is aimed at meeting the rapidly growing demand for access to SomaLogic’s highly multiplexed, cost-effective proteomic analyses.
“This agreement will greatly enhance our current microarray offerings by expanding them into the rapidly growing proteomics market,” said Jacob Thaysen, vice president and general manager of Agilent’s Genomics Solutions Division. “SomaLogic’s cutting-edge proteomic technology makes them an ideal partner for us to increase our presence in this growing market.”
“Agilent’s custom microarrays have been a critical element in our development of the SOMAscan assay over the past several years,” said Larry Gold, Ph.D., chairman and CEO of SomaLogic. “We are delighted that our partnership is expanding to make the technology even more accessible to researchers everywhere.”
Terms of the agreement were not disclosed.
SomaLogic, Inc., is a privately held biomarker discovery and clinical diagnostics company based in Boulder, Colo. The company's mission is to use its proprietary proteomic technology to develop a wide range of enhanced protein-analysis tools and reagents for the life sciences community, to facilitate biomarker discovery and validation for diagnostic and therapeutic applications, and to develop and commercialize clinical diagnostic products that will improve the delivery of health care by offering timely and accurate diagnostic information to physicians and their patients. Further information about SomaLogic can be found at www.somalogic.com.
The SOMAscan proteomic assay utilizes SomaLogic’s proprietary Slow Off-rate Modified Aptamer (SOMAmer) affinity reagents to cost-effectively detect and measure 1129 protein analytes across a wide dynamic range in as little as 50 µl of biological sample, with a throughput of nearly a thousand samples per week, producing millions of useful data points in a short time. Further information about the applications of this breakthrough proteomic technology can be found at www.somalogic.com/technology.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world’s premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics, and communications. The company’s 20,500 employees serve customers in more than 100 countries. Agilent had revenues of $6.9 billion in fiscal 2012. Information about Agilent is available at www.agilent.com.
NOTE TO EDITORS: Further technology, corporate citizenship, and executive news is available on the Agilent news site at www.agilent.com/go/news.
|TRADE NEWS: Agilent Technologies and MRM Proteomics Introduce First Commercial Kits for Quality Control of MRM-Based Quantitative Plasma Proteomic Workflows ()|
|Exlites Enters Agreement to Obtain New Products That Provide Cutting Edge Medical Technology (2013/8/12)|
|TRADE NEWS: Agilent Technologies Expands World’s Most Flexible PNA-X Network Analyzer for Active Device Test With 8.5-GHz Model (2014/4/2)|
|TRADE NEWS: Agilent Technologies Announces Expanded Business Relationship with Gradient Design Automation ()|
|TRADE NEWS: Agilent Technologies Expands Catalog of SureFISH Break-Apart Probes (2013/11/13)|
|TRADE NEWS: Agilent Technologies to Participate in Next-Generation Radio Access Network Joint Demonstration with China Mobile at Mobile World Congress (2014/2/24)|
|Agilent Technologies Signs Agreement to Acquire Assets from ABC Instrumentación Analítica (2013/9/4)|
|TRADE NEWS: Agilent Technologies Oligo Design Tool Expanded to Include Custom CGH, ChIP-on-Chip, DNA Methylation Array Capabilities (2013/11/18)|
|TRADE NEWS: Agilent Technologies Announces Agreement with Picometrics Technologies to Offer CE-LIF, CE-LIF-MS Solutions for Biopharmaceutical Applications (2014/1/16)|
|TRADE NEWS: Agilent Technologies Expands Next-Generation Sequencing Target-Enrichment Platform with SureCall Software Upgrade (2014/2/12)|
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.
Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.